Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation Trials, LLC (AFT) and the Austrian Breast and Colorectal Cancer Study Group ...
US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Molecular Oncology comparing the performance of mean ...
Clinical utility study in stage I-IV colorectal cancer (CRC) evaluates how adjuvant treatment decisions are impacted by using the Signatera™ MRD test AUSTIN, Texas, March 11, 2022 /PRNewswire/ -- ...
Signatera outperformed all available risk stratification tools in postoperative and post-definitive therapy settings This recently published, real-world, multi-center, retrospective study analyzed 233 ...
AUSTIN, Texas, May 31, 2022 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that new data on its personalized and tumor-informed molecular ...
Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...
The HEROES trial explores de-escalation of anti-HER2 therapy in metastatic HER2+ breast cancer using the Signatera test to guide treatment decisions. The trial aims to enroll 170 patients, focusing on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results